ArticleEuropean urology focus2019
Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes.
Article in European urology focus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 40 citations in OpenAlex.
- Outcomes of Adjuvant Radiation Therapy in Penile Cancer.Advances in radiation oncology · 2026Article
- Unveiling the variations in penile cancer care: identifying knowledge gaps and research priorities.BMJ oncology · 2026Review
- Demographics, Clinical Characteristics, and a Stage-Based Analysis of Treatments and Outcomes for Squamous Cell Carcinoma of the Penis.Cancer reports (Hoboken, N.J.) · 2025Article
- The role of radiotherapy in the management of squamous cell cancer of the penis.World journal of urology · 2023Review
- N4-acetylcytidine-dependent GLMP mRNA stabilization by NAT10 promotes head and neck squamous cell carcinoma metastasis and remodels tumor microenvironment through MAPK/ERK signaling pathway.Cell death & disease · 2023Article
- Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer.Asian journal of urology · 2022Review
- Patient reported outcomes in advanced penile cancer.Urologic oncology · 2022Article
- Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review.Frontiers in oncology · 2022Article
- An update on treatment of penile cancer.Therapeutic advances in medical oncology · 2022Review
- Impact of radiation therapy on perineal urethrostomy for penile cancer.Clinical and translational radiation oncology · 2021Article
- Adding radiotherapy based on chemotherapy can improve cancer-specific survival in N3 penile cancer: a SEER-based study.Translational andrology and urology · 2020Article
- Tumor Microenvironment in Penile Cancer.Advances in experimental medicine and biology · 2020Review
- Recent advances in the management of penile cancer.F1000Research · 2019Review
- Pelvic lymph node dissection alone versus adjuvant radiotherapy in node positive penile cancer: A systematic review.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundIn head and neck cancer, the presence of extranodal extension (ENE) in lymph nodes (LNs) has been shown prospectively to require adding chemotherapy to postoperative radiation therapy (RT). Limited data exist regarding ENE in LNs from primary penile cancer (PeCa).
objectiveTo determine the association of RT and ENE in PeCa. DESIGN, SETTING, AND
participantsWe retrospectively analyzed the outcomes of 93 patients with pT1-4 N3 M0 (American Joint Committee on Cancer 7th edition) squamous cell carcinoma of the penis across four international centers.
interventionIf the inguinal nodal specimen had ENE or two or more positive inguinal LNs, RT was delivered to an ipsilateral inguinal field. An ipsilateral pelvic field was added for positive pelvic LNs on dissection. The delivered dose was usually 50Gy in 25 daily fractions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinical and demographic characteristics of relapse-free (RFS), disease-specific (DSS), and overall (OS) survival were compared by ENE status and receipt of adjuvant RT. RESULTS AND LIMITATIONS: Seventy-two percent of patients had inguinal ENE, and 49% had pelvic ENE. On multivariable analysis (MVA) of ENE-negative patients, an OS benefit was noted with postoperative chemotherapy (p=0.038) and inguinopelvic RT (p=0.037). RFS suffered with worsening grade of the lesion (moderately: p=0.027; poorly: p=0.038), but was improved with groin (p=0.016) and inguinopelvic (p=0.006) RT. On MVA of patients with ENE, inguinopelvic RT was associated with better DSS (p=0.041). Grade impacted DSS (moderately: p=0.043; poorly: p=0.033), and poorly differentiated lesions impacted RFS (p=0.013).
conclusionsInguinopelvic RT may benefit regional control in PeCa patients with positive pelvic LNs, but this appears to be limited to those without ENE. PATIENT SUMMARY: For patients with penile cancer and positive pelvic lymph nodes, postoperative radiation therapy was found to decrease the likelihood of disease recurrence in the groin or pelvis only if extranodal extension was absent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.